DEVELOPMENT OF MAPATUMUMAB, A FULLY HUMAN AGONISTIC MONOCLONAL ANTIBODY WHICH TARGETS AND ACTIVATES THE TRAIL-RECEPTOR-1

被引：0
|
作者：
Gallant, G. J. A. [1 ]
机构：
[1] Human Genome Sci, Rockville, MD USA
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：25 / 25
页数：1
相关论文
共 50 条
  • [31] Phase I and pharmacokinetic study of HGS-ETR2, a fully human agonistic monoclonal antibody to TRAIL-R2, in patients with advanced solid malignancies.
    Attard, G
    Plummer, RE
    De Bono, JS
    Bale, C
    Fong, P
    Barrett, M
    Fox, NL
    Howard, T
    Ullrich, S
    Calvert, H
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9060S - 9060S
  • [32] Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non-Small-Cell Lung Cancer
    von Pawel, Joachim
    Harvey, Jimmie H.
    Spigel, David R.
    Dediu, Mircea
    Reck, Martin
    Cebotaru, Cristina L.
    Humphreys, Robin C.
    Gribbin, Matthew J.
    Fox, Norma Lynn
    Camidge, D. Ross
    CLINICAL LUNG CANCER, 2014, 15 (03) : 188 - +
  • [33] Results of a phase 2 trial of HGS-ETR1 (agonistic human monoclonal antibody to TRAIL receptor 1) in subjects with relapsed/recurrent non-small cell lung cancer (NSCLC)
    Bonomi, P
    Greco, F
    Crawford, J
    Kelly, K
    Oh, Y
    Klein, J
    LUNG CANCER, 2005, 49 : S238 - S238
  • [34] Development and characterization of DIA 12.3, a fully human intact anti-CEACAM1 monoclonal antibody
    Centonze, Michela
    Fiori, Valentina
    Kujawski, Maciej
    Li, Lin
    Wong, Patty
    Williams, Lindsay
    Di Mambro, Tomas
    Dominici, Sabrina
    Sparti, Angelo
    Shively, John E.
    Magnani, Mauro
    PLOS ONE, 2024, 19 (02):
  • [35] Apomab, a fully human agonistic DR5 monoclonal antibody inhibits tumor growth and osteolysis in murine models of breast cancer development and progression
    Zinonos, Irene
    Labrinidis, Agatha
    Liapis, Vasilios
    Hay, Shelley
    Lee, Michelle
    Ponomarev, Vladimir
    Diamond, Peter
    Zannettino, Andrew
    Findlay, David
    Evdokiou, Andreas
    CANCER RESEARCH, 2009, 69
  • [36] Apomab, a fully human agonistic DR5 monoclonal antibody inhibits tumour growth and osteolysis in murine models of breast cancer development and progression
    Zinonos, I.
    Labrinidis, A.
    Liapis, V.
    Hay, S.
    Lee, M.
    Ponomarev, V.
    Diamond, P.
    Zannettino, A. C. W.
    Findlay, D. M.
    Evdokiou, A.
    BONE, 2009, 44 : S54 - S54
  • [37] APOMAB, A FULLY HUMAN AGONISTIC DR5 MONOCLONAL ANTIBODY INHIBITS TUMOUR GROWTH AND OSTEOLYSIS IN MURINE MODELS OF BREAST CANCER DEVELOPMENT AND PROGRESSION
    Evdokiou, Andreas
    ADVANCES IN TNF FAMILY RESEARCH, 2011, 691 : 727 - 728
  • [38] Tanibirumab (TTAC-0001): A fully human monoclonal antibody targets vascular endothelial growth factor receptor 2 (VEGFR-2)
    Sang Hoon Lee
    Archives of Pharmacal Research, 2011, 34 : 1223 - 1226
  • [39] Activity of Apomab, a fully human agonistic DR5 monoclonal antibody, in models of non-Hodgkin's lymphoma
    Daniel, Dylan L.
    Yang, Becky
    Totpal, Klara
    Wagner, Klaus
    Yee, Sharon
    Ross, Sarajane
    Ashkenazi, Avi
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3442S - 3442S
  • [40] Tanibirumab (TTAC-0001): A Fully Human Monoclonal Antibody Targets Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2)
    Lee, Sang Hoon
    ARCHIVES OF PHARMACAL RESEARCH, 2011, 34 (08) : 1223 - 1226
12345